These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 6193548)

  • 1. Gamma-hydroxybutyrate in the treatment of schizophrenia.
    Levy MI; Davis BM; Mohs RC; Trigos GC; Mathé AA; Davis KL
    Psychiatry Res; 1983 May; 9(1):1-8. PubMed ID: 6193548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Melperone in the treatment of schizophrenia.
    Bjerkenstedt L
    Acta Psychiatr Scand Suppl; 1989; 352():35-9. PubMed ID: 2479227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gamma-hydroxybutyrate treatment of schizophrenia: a pilot study.
    Schulz SC; van Kammen DP; Buchsbaum MS; Roth RH; Alexander P; Bunney WE
    Pharmacopsychiatria; 1981 Jul; 14(4):129-34. PubMed ID: 7280012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of raclopride treatment on plasma and CSF HVA: relationships with clinical improvement in male schizophrenics.
    Csernansky JG; Newcomer JW; Jackson K; Lombrozo L; Faull KF; Zipursky R; Pfefferbaum A; Faustman WO
    Psychopharmacology (Berl); 1994 Nov; 116(3):291-6. PubMed ID: 7534423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical, biochemical, and hormonal aspects of treatment with Des-tyr1-gamma-endorphin in schizophrenia.
    Verhoeven WM; van Ree JM; Westenberg HG; Krul JM; Brouwer GJ; Thijssen JH; de Wied D; van Praag HM; Ceulemans DL; Kahn RS
    Psychiatry Res; 1984 Apr; 11(4):329-46. PubMed ID: 6204351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and biologic response to clozapine in patients with schizophrenia. Crossover comparison with fluphenazine.
    Pickar D; Owen RR; Litman RE; Konicki E; Gutierrez R; Rapaport MH
    Arch Gen Psychiatry; 1992 May; 49(5):345-53. PubMed ID: 1375019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of gamma-hydroxybutyrate versus placebo in treating narcolepsy-cataplexy: double-blind subjective measures.
    Scrima L; Hartman PG; Johnson FH; Hiller FC
    Biol Psychiatry; 1989 Aug; 26(4):331-43. PubMed ID: 2669980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monoamine neurotransmitter interactions in drug-free and neuroleptic-treated schizophrenics.
    Hsiao JK; Colison J; Bartko JJ; Doran AR; Konicki PE; Potter WZ; Pickar D
    Arch Gen Psychiatry; 1993 Aug; 50(8):606-14. PubMed ID: 7688209
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low cerebrospinal fluid homovanillic acid-5-hydroxyindoleacetic acid ratio predicts clozapine efficacy: a replication.
    Risch SC; Lewine RR
    Arch Gen Psychiatry; 1993 Aug; 50(8):670. PubMed ID: 7688212
    [No Abstract]   [Full Text] [Related]  

  • 10. Clonidine treatment of schizophrenia: can we predict treatment response?
    van Kammen DP; Peters JL; van Kammen WB; Rosen J; Yao JK; McAdam D; Linnoila M
    Psychiatry Res; 1989 Mar; 27(3):297-311. PubMed ID: 2469097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gamma-hydroxybutyric acid for treatment of alcohol withdrawal syndrome.
    Gallimberti L; Canton G; Gentile N; Ferri M; Cibin M; Ferrara SD; Fadda F; Gessa GL
    Lancet; 1989 Sep; 2(8666):787-9. PubMed ID: 2571021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationships between drug concentrations in serum and CSF, clinical effects and monoaminergic variables in schizophrenic patients treated with sulpiride or chlorpromazine.
    Alfredsson G; Bjerkenstedt L; Edman G; Härnryd C; Oxenstierna G; Sedvall G; Wiesel FA
    Acta Psychiatr Scand Suppl; 1984; 311():49-74. PubMed ID: 6199949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The relationship between clinical and biochemical changes following neuroleptic treatment in schizophrenia.
    Cooper SJ; Leahey W; Liddle J; King DJ
    Schizophr Res; 1990; 3(4):261-7. PubMed ID: 1703780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apomorphine and schizophrenia. Treatment, CSF, and neuroendocrine responses.
    Levy MI; Davis BM; Mohs RC; Kendler KS; Mathé AA; Trigos G; Horvath TB; Davis KL
    Arch Gen Psychiatry; 1984 May; 41(5):520-4. PubMed ID: 6372737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cerebrospinal fluid and plasma monoamine metabolites and their relation to psychosis. Implications for regional brain dysfunction in schizophrenia.
    Pickar D; Breier A; Hsiao JK; Doran AR; Wolkowitz OM; Pato CN; Konicki PE; Potter WZ
    Arch Gen Psychiatry; 1990 Jul; 47(7):641-8. PubMed ID: 1694425
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CSF concentrations of neurotensin in schizophrenia: an investigation of clinical and biochemical correlates.
    Breslin NA; Suddath RL; Bissette G; Nemeroff CB; Lowrimore P; Weinberger DR
    Schizophr Res; 1994 Apr; 12(1):35-41. PubMed ID: 7517175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of narcolepsy with gamma-hydroxybutyrate. A review of clinical and sleep laboratory findings.
    Mamelak M; Scharf MB; Woods M
    Sleep; 1986; 9(1 Pt 2):285-9. PubMed ID: 3704454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GHB and GABA.
    Plantey F
    Am J Psychiatry; 1977 Sep; 134(9):1045-6. PubMed ID: 900292
    [No Abstract]   [Full Text] [Related]  

  • 19. CSF monoamine metabolites in schizophrenic patients.
    Gattaz WF; Waldmeier P; Beckmann H
    Acta Psychiatr Scand; 1982 Nov; 66(5):350-60. PubMed ID: 6184954
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduction of MOPEG levels in cerebrospinal fluid of psychotic women after electroconvulsive treatment.
    Härnryd C; Bjerkenstedt L; Grimm VE; Sedvall G
    Psychopharmacology (Berl); 1979 Aug; 64(2):131-4. PubMed ID: 115032
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.